Scarica l'app Stockscreener
3.10
0.32%
-0.010
Precedente Chiudi:
$3.11
Aprire:
$3.11
Volume 24 ore:
6.52M
Relative Volume:
1.71
Capitalizzazione di mercato:
$361.33M
Reddito:
$6.65M
Utile/perdita netta:
$-136.32M
Rapporto P/E:
-2.7011
EPS:
-1.1477
Flusso di cassa netto:
$-112.04M
1 W Prestazione:
+6.16%
1M Prestazione:
+65.78%
6M Prestazione:
+195.24%
1 anno Prestazione:
+167.24%
Intervallo 1D:
$2.82
$3.14
Intervallo di 1 settimana:
$2.82
$3.155
Portata 52W:
$0.91
$3.21
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
3.10 | 361.33M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-19 | Ripresa | Jefferies | Buy |
| 2025-10-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11 - Moomoo
Fate Therapeutics’ FT-839 gains IND clearance - BioWorld News
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? - Kalkine Media
FT819 shows first clinical activity in systemic sclerosis - CRISPR Medicine News
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - Moomoo
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
Sector Update: Healthcare - Moomoo
Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - marketscreener.com
Fate Therapeutics gains after IND clearance (FATE:NASDAQ) - Seeking Alpha
Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate - marketscreener.com
FDA clears Fate Therapeutics' FT839 for autoimmune trial push - Stock Titan
Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE - MarketBeat
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) - Seeking Alpha
Fate Therapeutics looks to its pipeline as investors weigh long-term prospects - ad-hoc-news.de
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com
Fate Therapeutics Announces Preliminary FT819 Data in Systemic Sclerosis for ISSCR 2026 Presentation - Quiver Quantitative
Fate Therapeutics to present FT819 data at stem cell meeting By Investing.com - Investing.com Canada
Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan
Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et
Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - ad-hoc-news.de
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - ad-hoc-news.de
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView
Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView
Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Price to book forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Enterprise value to EBITDA forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Price to sales forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
FATE Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities - The Globe and Mail
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):